Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-07-14
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses its Recursion OS platform, proprietary data, automated labs, and partnerships to discover and develop medicines.
ai biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Gates a Valuable Platform
The upside case is a rerating from cash-backed optionality to a repeatable drug-creation engine. The next 18 months matter because one regulatory path update and one more internal proof point can reshape both partner leverage and financing terms.

Analysis

Thesis
Recursion can grow from a cash-backed AI drug-discovery option into a repeatable drug-creation company if 2026-2028 proves three things at once: a workable REC-4881 regulatory path, a second validating internal readout, and partner economics that reward verified outcomes rather than discovery labor.
Last Economy Alignment
Cheaper cognition directly strengthens its data-model-lab loop, and value capture is tied to proprietary experiments and drug rights rather than seat licenses. The score stops short of elite because biology, regulators, and cash runway still bottleneck scaling.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.0x (from 5 most recent analyses)
Reasoning
This is a rerating case, not a straight-line margin story. The stock can work if one lead asset gets a credible regulatory path, a second internal program validates repeatability, and collaborations shift from one-off work toward richer downstream economics. That mix would let investors value the business less like cash-funded biotech optionality and more like a repeatable drug-creation engine.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is translation: the platform may speed discovery without reliably improving human outcomes. If REC-4881’s FDA path disappoints, a second owned program slips, or partners hesitate to opt in, Recursion can drift back toward lumpy discovery revenue while burning cash into a financing cycle. Governance cleanup matters, but biology and regulatory proof remain the real swing factors.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.54
They control a loop of proprietary data, automated labs, compute, and drug rights, so cheaper AI should help them make more shots on goal. The risk is that biology and regulators, not software, still decide value, so without real clinical wins the platform can look replaceable.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case